*Форменная одежда ВКС*

via forma full 5 https://ift.tt/KBI2W7A Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3599964.html)

*Форма и камуфляж*

via forma full 5 https://ift.tt/1YGH8Zy Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3595834.html)

Форменная одежда ВКС

via forma full 5 https://ift.tt/KBI2W7A Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...

*Тактические брюки*

via forma full 5 https://ift.tt/G5jesgn Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3597772.html)

Форма и камуфляж

via forma full 5 https://ift.tt/1YGH8Zy Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...

Тактические брюки

via forma full 5 https://ift.tt/G5jesgn Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...

*Что такое эпизиотомия и как после неё восстановиться*

Операция облегчает роды, но она нужна не всем.
[Read more...](https://lifehacker.ru/chto-takoe-epiziotomiya/)

*What are you not embarrassed to admit?*

52m, and I’m afraid of the dark. submitted by /u/jonniebaby2000 to r/RandomThoughts [link] [comments]
[Read more...](https://www.reddit.com/r/RandomThoughts/comments/19dd0wc/what_are_you_not_embarrassed_to_admit/)

What are you not embarrassed to admit?

52m, and I’m afraid of the dark. submitted by /u/jonniebaby2000 to r/RandomThoughts link comments
Read more...

*Best friends forever*

submitted by /u/White_Power_Hacker to r/Awww [link] [comments]
[Read more...](https://www.reddit.com/r/Awww/comments/19detj1/best_friends_forever/)

Best friends forever

submitted by /u/WhitePowerHacker to r/Awww link comments
Read more...

*She’s gunna be führious*

submitted by /u/gaping-bingus to r/rareinsults [link] [comments]
[Read more...](https://www.reddit.com/r/rareinsults/comments/19dgvlg/shes_gunna_be_f%C3%BChrious/)

She’s gunna be führious

submitted by /u/gaping-bingus to r/rareinsults link comments
Read more...

*Johnson & Johnson holds 2024 profit forecast steady after solid Q4 earnings*

Updated at 7:16 AM EST Johnson & Johnson (JNJ) - Get Free Report posted modestly better-than-expected fourth-quarter earnings Tuesday, while reiterating its full-year profit forecast, thanks to solid sales for its psoriasis and cancer therapies. Adjusted earnings for the three months ended in December were $2.29 a share, down 2.6% from the same period in 2022 but a penny ahead of the Wall Street consensus forecast. Related: Humana plunges on major health insurance warning; UnitedHealth, CVS tumble Group revenue, Johnson & Johnson said, slipped 9.7% to $21.4 billion, exceeding analysts' estimates of a $21 billion tally. Pharmaceutical sales were up 5.4% to $13.72 billion while Medtech sales jumped 13% to $7.67 billion. Consumer health sales were spun off to Kenvue, the group's stand-alone entity, in early 2023. Johnson & Johnson reiterated that 2024 earnings should come in around $10.55 to $10.75 a share. Operational sales are expected to rise 5% to 6%, suggesting a tally between $88.2 billion and $89 billion. The new figures exclude the impact of Kenvue.J&J CEO: Entering '24 in 'position of strength' "Johnson & Johnson’s full-year 2023 results reflect the breadth and competitiveness of our business and our relentless focus on delivering for patients,” said CEO Joaquin Duato. “We have entered 2024 from a position of strength, and I am confident in our ability to lead the next wave of health innovation.” Johnson & Johnson shares were marked 0.23% lower in premarket trading immediately following the earnings release to indicate an opening bell price of $162.10 each, a move that would extend the stock's six-month decline to around 5.3%. Earlier this month, Johnson & Johnson said it would pay $28 a share in cash for cancer-drug specialists Ambx Biopharma (AMAM) - Get Free Report, a deal that values the La Jolla, Calif., biotech at around $2 billion. Ambrx focuses on so-called antibody drug conjugates, which attack cancer cells from the outside without damaging healthy tissues in the rest of the body. The group has used its techniques to target breast cancer and prostate cancer in recent clinical trials and has won fast-track designation for its ARX517 prostate therapy from the U.S. Food and Drug Administration.Related: Veteran fund manager picks favorite stocks for 2024
[Read more...](https://www.thestreet.com/investing/stocks/johnson-johnson-holds-2024-profit-forecast-steady-after-solid-q4-earnings)

*Verizon leaps as key factor in outlook adds fuel to Q4 earnings beat*

Verizon (VZ) - Get Free Report posted better-than-expected fourth quarter earnings Tuesday, while forecasting solid 2024 profits thanks in part to its flexible wireless plans and promotions linked to Apple's (AAPL) - Get Free Report new iPhone 15. Adjusted non-GAAP earnings for the three months ended in December were $1.08 a share, down 9.2% from the same period in 2022 but topping the Wall Street consensus forecast of $1.07 per share. Related: Iconic retailer rejects multibillion-dollar takeover bid Group revenue, Verizon said, slipped 0.4% from a year earlier to $35.1 billion, just ahead of analysts' estimates of a $34.58 billion tally. Verzion's postpaid additions for the quarter were pegged at 446,000, the highest in nearly two years and double analysts' estimates. That's thanks in part to hybrid plans that include streaming subscriptions such as Netflix (NFLX) - Get Free Report and Max. (WBD) - Get Free Report Looking into the coming year, Verizon sees wireless revenue growing 2% to 3.5%. Adjusted earnings are estimated in the region of $4.50 to $4.70 per share, compared with an LSEG forecast of around $4.59 per share.Verizon CEO: Balance of growth, profitability "After delivering continuous improvement throughout 2023, we ended the year strong and continue to pursue the right balance of growth and profitability," Chief Executive Hans Vestberg said in a statement. Shutterstock The year "2023 was a year of change. We have the right assets and the best team in place and are well-positioned for growth in 2024." Verizon shares were marked 1.6% higher in premarket trading immediately following the earnings release to indicate an opening bell price of $40.20 each. Technology:AI takes this stock to record; investors look past Magnificent 7 Amazon plan to paywall a popular product hits a roadblock AI stock soars on new guidance (it's not Nvidia!) Last November, the group named Tony Skiadas as full-time chief financial office. Vestberg said the move positioned the company veteran "to steer us through the current economic volatility and our industry's changing landscape." Verizon's ongoing deployment of its 5G network, built in part on the $53 billion purchase of new C-Band spectrum from the U.S. government, remains a key plank in the group's growth prospects Related: Veteran fund manager picks favorite stocks for 2024
[Read more...](https://www.thestreet.com/investing/stocks/verizon-leaps-as-2024-subscriber-outlook-adds-fuel-to-q4-earnings-beat)

Johnson & Johnson holds 2024 profit forecast steady after solid Q4 earnings

Updated at 7:16 AM EST Johnson & Johnson (JNJ) - Get Free Report posted modestly better-than-expected fourth-quarter earnings Tuesday, while reiterating its full-year profit forecast, thanks to solid sales for its psoriasis and cancer therapies. Adjusted earnings for the three months ended in December were $2.29 a share, down 2.6% from the same period in 2022 but a penny ahead of the Wall Street consensus forecast. Related: Humana plunges on major health insurance warning; UnitedHealth, CVS tumble Group revenue, Johnson & Johnson said, slipped 9.7% to $21.4 billion, exceeding analysts' estimates of a $21 billion tally. Pharmaceutical sales were up 5.4% to $13.72 billion while Medtech sales jumped 13% to $7.67 billion. Consumer health sales were spun off to Kenvue, the group's stand-alone entity, in early 2023. Johnson & Johnson reiterated that 2024 earnings should come in around $10.55 to $10.75 a share. Operational sales are expected to rise 5% to 6%, suggesting a tally between $88.2 billion and $89 billion. The new figures exclude the impact of Kenvue.J&J CEO: Entering '24 in 'position of strength' "Johnson & Johnson’s full-year 2023 results reflect the breadth and competitiveness of our business and our relentless focus on delivering for patients,” said CEO Joaquin Duato. “We have entered 2024 from a position of strength, and I am confident in our ability to lead the next wave of health innovation.” Johnson & Johnson shares were marked 0.23% lower in premarket trading immediately following the earnings release to indicate an opening bell price of $162.10 each, a move that would extend the stock's six-month decline to around 5.3%. Earlier this month, Johnson & Johnson said it would pay $28 a share in cash for cancer-drug specialists Ambx Biopharma (AMAM) - Get Free Report, a deal that values the La Jolla, Calif., biotech at around $2 billion. Ambrx focuses on so-called antibody drug conjugates, which attack cancer cells from the outside without damaging healthy tissues in the rest of the body. The group has used its techniques to target breast cancer and prostate cancer in recent clinical trials and has won fast-track designation for its ARX517 prostate therapy from the U.S. Food and Drug Administration.Related: Veteran fund manager picks favorite stocks for 2024
Read more...

Verizon leaps as key factor in outlook adds fuel to Q4 earnings beat

Verizon (VZ) - Get Free Report posted better-than-expected fourth quarter earnings Tuesday, while forecasting solid 2024 profits thanks in part to its flexible wireless plans and promotions linked to Apple's (AAPL) - Get Free Report new iPhone 15. Adjusted non-GAAP earnings for the three months ended in December were $1.08 a share, down 9.2% from the same period in 2022 but topping the Wall Street consensus forecast of $1.07 per share. Related: Iconic retailer rejects multibillion-dollar takeover bid Group revenue, Verizon said, slipped 0.4% from a year earlier to $35.1 billion, just ahead of analysts' estimates of a $34.58 billion tally. Verzion's postpaid additions for the quarter were pegged at 446,000, the highest in nearly two years and double analysts' estimates. That's thanks in part to hybrid plans that include streaming subscriptions such as Netflix (NFLX) - Get Free Report and Max. (WBD) - Get Free Report Looking into the coming year, Verizon sees wireless revenue growing 2% to 3.5%. Adjusted earnings are estimated in the region of $4.50 to $4.70 per share, compared with an LSEG forecast of around $4.59 per share.Verizon CEO: Balance of growth, profitability "After delivering continuous improvement throughout 2023, we ended the year strong and continue to pursue the right balance of growth and profitability," Chief Executive Hans Vestberg said in a statement. Shutterstock The year "2023 was a year of change. We have the right assets and the best team in place and are well-positioned for growth in 2024." Verizon shares were marked 1.6% higher in premarket trading immediately following the earnings release to indicate an opening bell price of $40.20 each. Technology:AI takes this stock to record; investors look past Magnificent 7 Amazon plan to paywall a popular product hits a roadblock AI stock soars on new guidance (it's not Nvidia!) Last November, the group named Tony Skiadas as full-time chief financial office. Vestberg said the move positioned the company veteran "to steer us through the current economic volatility and our industry's changing landscape." Verizon's ongoing deployment of its 5G network, built in part on the $53 billion purchase of new C-Band spectrum from the U.S. government, remains a key plank in the group's growth prospects Related: Veteran fund manager picks favorite stocks for 2024
Read more...

*Обзор Huawei MatePad Pro 13.2″ — флагманского планшета на замену ноутбуку*

В паре с клавиатурой гаджет превращается в удобный рабочий инструмент, а вот для игр может не подойти.
[Read more...](https://lifehacker.ru/obzor-huawei-matepad-pro-13-2/)

*You're now a Dev for Wilds. How would you change your main weapon?*

submitted by /u/Tech-Demon to r/MonsterHunter [link] [comments]
[Read more...](https://www.reddit.com/r/MonsterHunter/comments/19d8qsk/youre_now_a_dev_for_wilds_how_would_you_change/)

You're now a Dev for Wilds. How would you change your main weapon?

submitted by /u/Tech-Demon to r/MonsterHunter link comments
Read more...